Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs

(2020) Dr. Julie M. Janssen et al.   THERAPEUTIC DRUG MONITORING

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma

(2019) Julie M. Janssen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

(2019) Peter T Harrison et al.   SEMINARS IN CANCER BIOLOGY

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

(2019) B. van Veggel et al.   LUNG CANCER

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

(2018) Nicolas Floc'h et al.   MOLECULAR CANCER THERAPEUTICS

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

(2016) Yoshiko Urata et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

(2015) DE Coutant et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

(2015) Toshiyuki Hirano et al.   Oncotarget

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice

(2015) Aaron P. Mitchell et al.   Journal of Oncology Practice

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients

(2014) C. Narjoz et al.   INVESTIGATIONAL NEW DRUGS

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

(2013) J-Y Douillard et al.   BRITISH JOURNAL OF CANCER

Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index

(2013) Lisa Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times

(2009) Yanfeng Wang et al.   THERAPEUTIC DRUG MONITORING